Back to top
more

Amarin (AMRN)

(Delayed Data from NSDQ)

$19.33 USD

19.33
252,892

+0.49 (2.60%)

Updated Oct 6, 2025 04:00 PM ET

After-Market: $19.35 +0.02 (0.10%) 7:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate

by Zacks Equity Research

TEVA starts IND-enabling studies for BD9, a dual-targeting multibody for asthma and eczema. Shares rise on the news.

Zacks Equity Research

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

by Zacks Equity Research

Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.

Zacks Equity Research

AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer

by Zacks Equity Research

AstraZeneca wins CHMP nod for Imfinzi combo in muscle-invasive bladder cancer, based on data from the phase III NIAGARA study.

Zacks Equity Research

GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma

by Zacks Equity Research

GSK wins CHMP nod for Blenrep combos in relapsed or refractory multiple myeloma. A decision in the EU is expected in the third quarter of 2025.

Zacks Equity Research

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

by Zacks Equity Research

SWTX wins CHMP backing for mirdametinib in NF1-PN. EU nod is expected in the third quarter of 2025.

Zacks Equity Research

Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases

by Zacks Equity Research

BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data.

Zacks Equity Research

EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort

by Zacks Equity Research

Exelixis' zanzalintinib/Opdivo combo shows superior efficacy for treating kidney cancer in an expansion cohort of the phase Ib/II STELLAR-002 study.

Zacks Equity Research

Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation

by Zacks Equity Research

The phase I study evaluates BAYRY's investigational GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial fibrillation.

Zacks Equity Research

ARMP Soars 72% in a Month Following Infectious Disease Study Success

by Zacks Equity Research

Armata Pharmaceuticals stock surges 72% in a month following superior efficacy results from a phase Ib/IIa study of AP-SA02 for treating an infectious disease.

Zacks Equity Research

CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies

by Zacks Equity Research

CRSP enters into a strategic partnership with Sirius Therapeutics for developing novel siRNA Therapies.

Zacks Equity Research

Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y

by Zacks Equity Research

AMRN reports better-than-expected results for the first quarter of 2025. However, the top and bottom lines decline on a year-over-year basis.

Zacks Equity Research

AMRN's Q4 Earnings Lag Estimates, Stock Down on Ratio Change Plan

by Zacks Equity Research

Amarin incurs a wider-than-expected loss in Q4. Revenues beat estimates. It plans to initiate a ratio change on its American Depositary Shares. Stock falls.

Zacks Equity Research

After Plunging -19.13% in 4 Weeks, Here's Why the Trend Might Reverse for Amarin (AMRN)

by Zacks Equity Research

Amarin (AMRN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction

by Zacks Equity Research

KRYS beat on both earnings and sales in the third quarter of 2024. Lead drug Vyjuvek's launch in the United States shows strong uptake.

Zacks Equity Research

Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales

by Zacks Equity Research

BHC's third-quarter adjusted earnings and revenues beat estimates. The increase in revenue guidance is positive.

Zacks Equity Research

Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

Kymera reports a narrower-than-expected loss in the third quarter. The company expects the current cash balance to provide a runway into mid-2027.

Zacks Equity Research

Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View

by Zacks Equity Research

BMY posts impressive third-quarter results, with both earnings and sales beating the respective estimates. The company also raises its annual earnings guidance.

Zacks Equity Research

Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates

by Zacks Equity Research

AMRN's third-quarter 2024 earnings meet estimates while revenues miss the same. Vascepa's sales in the United States decline year over year. Stock falls.

Zacks Equity Research

Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook

by Zacks Equity Research

EXEL tops on earnings and sales in the third quarter as lead drug Cabometyx maintains momentum. The company also raises its revenue guidance for 2024.

Zacks Equity Research

Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat

by Zacks Equity Research

Amarin's (AMRN) second-quarter 2024 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year. Stock down.

Zacks Equity Research

Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?

by Zacks Equity Research

Denali Therapeutics (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

Kymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the current cash balance to provide a runway into the first half of 2027.

Zacks Equity Research

Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Amarin (AMRN) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Zacks Equity Research

Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall

by Zacks Equity Research

Bausch's (BHC) first-quarter earnings and sales miss their respective estimates. Its shares fall in response to the results.

Zacks Equity Research

Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Amarin (AMRN) posts better-than-expected first-quarter 2024 results. Vascepa's sales in the United States continue to be hurt by generic competition.